Rebyota™
Drug - Rebyota™ (fecal microbiota, live - jslm) [Ferring Pharmaceuticals Inc.]
January 2025
Therapeutic area - Antibiotics, GI
Approval criteria
- Patient ≥ 18 years of age; AND
- Patient has a confirmed diagnosis of recurrent Clostridioides difficile infection (CDI) with a total of ≥ 3 episodes of CDI within 12 months; AND
- Antibiotic treatment for recurrent CDI must be completed 24 to 72 hours prior to initiation of Rebyota therapy; AND
- Rebyota is prescribed by, or in consultation with, an infectious disease or gastrointestinal specialist
Quantity limits
Billing for Rebyota
Rebyota must be billed as a medical claim.
Background
Rebyota is not indicated for treatment of CDI.
Questions
Provider Call Center (844) 575-7887